The Effect of Topical Bevacizumab on Corneal Neovascularization

0 736

Cited 0 times in

Cited 205 times in

Authors: Sang Woo Kim ; Byung Jin Ha ; Eung Kweon Kim ; Hungwon Tchah ; Tae-im Kim

MeSH: Administration, Topical ; Adolescent ; Adult ; Angiogenesis Inhibitors/administration & dosage* ; Angiogenesis Inhibitors/adverse effects ; Antibodies, Monoclonal/administration & dosage* ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized ; Bevacizumab ; Corneal Neovascularization/drug therapy* ; Corneal Neovascularization/physiopathology ; Epithelium, Corneal/drug effects ; Epithelium, Corneal/pathology ; Female ; Humans ; Intraocular Pressure/drug effects ; Male ; Middle Aged ; Prognosis ; Prospective Studies ; Tonometry, Ocular ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Visual Acuity/drug effects

Keywords: Administration, Topical ; Adolescent ; Adult ; Angiogenesis Inhibitors/administration & dosage* ; Angiogenesis Inhibitors/adverse effects ; Antibodies, Monoclonal/administration & dosage* ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized ; Bevacizumab ; Corneal Neovascularization/drug therapy* ; Corneal Neovascularization/physiopathology ; Epithelium, Corneal/drug effects ; Epithelium, Corneal/pathology ; Female ; Humans ; Intraocular Pressure/drug effects ; Male ; Middle Aged ; Prognosis ; Prospective Studies ; Tonometry, Ocular ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Visual Acuity/drug effects

Abstract: PURPOSE: To examine the effect of topical bevacizumab on corneal neovascularization (NV) over a period of 3 months.

DESIGN: Prospective, nonrandomized, masked observational case series.

PARTICIPANTS: Ten eyes of 7 patients with corneal NV.

METHODS: Patients received topical bevacizumab (1.25%) twice daily. Ophthalmic evaluations included visual acuity, slit-lamp examination, and tonometry.

MAIN OUTCOME MEASURES: Corneal NV and changes in ophthalmic evaluations.

RESULTS: Decreased corneal NV was noted in 7 of 10 eyes, usually within 1 month of treatment. Epitheliopathy (epithelial defect, epithelial erosion) was observed in 6 of 10 eyes, 1 resulting in corneal thinning. Adverse effects generally appeared during the second month of treatment.

CONCLUSIONS: Topical application of bevacizumab was effective in reducing corneal NV within the first month. However, by the second month there was an increased risk of adverse effects.

Full Text: http://www.sciencedirect.com/science/article/pii/S0161642008001760

Appears in Collections:: 1. College of Medicine (의과대학) > Dept. of Ophthalmology (안과학교실) > 1. Journal Papers

Yonsei Authors: Kim, Sang Woo(김상우)
Kim, Eung Kweon(김응권) https://orcid.org/0000-0002-1453-8042
Kim, Tae-Im(김태임) https://orcid.org/0000-0001-6414-3842
Ha, Byoung Jin(하병진)

Show full item record Find it @ YMLIB

YUHSpace: The Effect of Topical Bevacizumab on Corneal Neovascularization